Michael Bernd Ranke
Research Subjects
Research Interests
Michael Bernd Ranke has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Anders Lindberg
14 shared publications- H. A. Wollmann
University Children's Hospital, Growth Research Center, Tübingen, Germany
7 shared publications Kerstin Albertsson-Wikland
7 shared publicationsPatrick Wilton
7 shared publicationsDavid A. Price
6 shared publicationsEdward O. Reiter
5 shared publications
Latest Publications
- 8 April 2015
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 83 (5) , 358-360
Treatment with Recombinant Human Insulin-Like Growth Factor-1 in Severe Primary IGF Deficiency and Beyond
Advancement in the understanding of diseases is based on progress in the fields of basic and clinical research. The developments relating to the growth hormone (GH)-insulin-like growth factor (IGF) system vividly exemplify the dynamic process that has led to a deeper understanding of growth disorders and their treatment over the past decades. In the 1950s, growth hormone deficiency (GHD) in children was considered to be a disorder characterized by severe, permanent short stature caused by impaired GH secretion. The clinical presentation varied, and the disorder was treated by replacement with human GH. Since then, however, the discovery of multiple causes of GHD, at the anatomical, genetic and functional level, has vastly expanded our understanding of this disorder.
- 8 April 2015
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 83 (5) , 358-360
Treatment with Recombinant Human Insulin-Like Growth Factor-1 in Severe Primary IGF Deficiency and Beyond
Advancement in the understanding of diseases is based on progress in the fields of basic and clinical research. The developments relating to the growth hormone (GH)-insulin-like growth factor (IGF) system vividly exemplify the dynamic process that has led to a deeper understanding of growth disorders and their treatment over the past decades. In the 1950s, growth hormone deficiency (GHD) in children was considered to be a disorder characterized by severe, permanent short stature caused by impaired GH secretion. The clinical presentation varied, and the disorder was treated by replacement with human GH. Since then, however, the discovery of multiple causes of GHD, at the anatomical, genetic and functional level, has vastly expanded our understanding of this disorder.
- 26 February 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 79 (2) , 51-67
Towards Optimal Treatment with Growth Hormone in Short Children and Adolescents: Evidence and Theses
Treatment with growth hormone (GH) has become standard practice for replacement in GH-deficient children or pharmacotherapy in a variety of disorders with short stature. However, even today, the reported adult heights achieved often remain below the normal range. In addition, the treatment is expensive and may be associated with long-term risks. Thus, a discussion of the factors relevant for achieving an optimal individual outcome in terms of growth, costs, and risks is required. In the present review, the heterogenous approaches of treatment with GH are discussed, considering the parameters available for an evaluation of the short- and long-term outcomes at different stages of treatment. This discourse introduces the potential of the newly emerging prediction algorithms in comparison to other more conventional approaches for the planning and evaluation of the response to GH. In rare disorders such as those with short stature, treatment decisions cannot easily be deduced from personal experience. An interactive approach utilizing the derived experience from large cohorts for the evaluation of the individual patient and the required decision-making may facilitate the use of GH. Such an approach should also lead to avoiding unnecessary long-term treatment in unresponsive individuals.
- 26 February 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 79 (2) , 51-67
Towards Optimal Treatment with Growth Hormone in Short Children and Adolescents: Evidence and Theses
Treatment with growth hormone (GH) has become standard practice for replacement in GH-deficient children or pharmacotherapy in a variety of disorders with short stature. However, even today, the reported adult heights achieved often remain below the normal range. In addition, the treatment is expensive and may be associated with long-term risks. Thus, a discussion of the factors relevant for achieving an optimal individual outcome in terms of growth, costs, and risks is required. In the present review, the heterogenous approaches of treatment with GH are discussed, considering the parameters available for an evaluation of the short- and long-term outcomes at different stages of treatment. This discourse introduces the potential of the newly emerging prediction algorithms in comparison to other more conventional approaches for the planning and evaluation of the response to GH. In rare disorders such as those with short stature, treatment decisions cannot easily be deduced from personal experience. An interactive approach utilizing the derived experience from large cohorts for the evaluation of the individual patient and the required decision-making may facilitate the use of GH. Such an approach should also lead to avoiding unnecessary long-term treatment in unresponsive individuals.
- Open Access
- 1 June 2011
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 11 (1) , 38
Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database)
Mathematical models can be developed to predict growth in short children treated with growth hormone (GH). These models can serve to optimize and individualize treatment in terms of height outcomes and costs. The aims of this study were to compile existing prediction models for short children born SGA (SGA), to develop new models and to validate the algorithms.
- 1 June 2011
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 11 (1) , 38
Open AccessPrediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database)
Mathematical models can be developed to predict growth in short children treated with growth hormone (GH). These models can serve to optimize and individualize treatment in terms of height outcomes and costs. The aims of this study were to compile existing prediction models for short children born SGA (SGA), to develop new models and to validate the algorithms.
- 30 April 2010
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 74 (4) , 259-266
Height at Start, First-Year Growth Response and Cause of Shortness at Birth Are Major Determinants of Adult Height Outcomes of Short Children Born Small for Gestational Age and Silver-Russell Syndrome Treated with Growth Hormone: Analysis of Data from KIGS
Background/Aims: There is limited information about adult height (AH) outcomes and the factors influencing outcomes of growth hormone (GH) therapy in short children born small for gestational age (SGA). Methods: AH (SDS) and Δheight (SDS) from GH start to AH were analyzed in 161 SGA children who had reached AH (55 with Silver-Russell syndrome, SRS). Results: SGA patients treated to AH were started on GH (median) 0.25 mg/kg/week at an age of 7.8 years with a height of –3.8 SDS. AH after 7.7 years was –2.2 SDS and –1.1 SDS below mid-parental height (MPH). AH (SDS) was explained by: height (SDS) at GH start (+), Δheight (SDS) 1st year on GH (+), years on GH (+), maternal height (SDS) (+), length (SDS) at birth (+), and the diagnosis of SRS (–) (explained variability 70%; error 0.6 SD). Gain in height (SDS) was explained by: Δheight (SDS) 1st year on GH (+), years on GH (+), height – MPH (SDS) at GH start (–) (explained variability 60%; error 0.7 SD). Conclusions: Algorithms for AH outcomes provides useful information about the potential of long-term growth on GH in short children born SGA.
- 30 April 2010
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 74 (4) , 259-266
Height at Start, First-Year Growth Response and Cause of Shortness at Birth Are Major Determinants of Adult Height Outcomes of Short Children Born Small for Gestational Age and Silver-Russell Syndrome Treated with Growth Hormone: Analysis of Data from KIGS
Background/Aims: There is limited information about adult height (AH) outcomes and the factors influencing outcomes of growth hormone (GH) therapy in short children born small for gestational age (SGA). Methods: AH (SDS) and Δheight (SDS) from GH start to AH were analyzed in 161 SGA children who had reached AH (55 with Silver-Russell syndrome, SRS). Results: SGA patients treated to AH were started on GH (median) 0.25 mg/kg/week at an age of 7.8 years with a height of –3.8 SDS. AH after 7.7 years was –2.2 SDS and –1.1 SDS below mid-parental height (MPH). AH (SDS) was explained by: height (SDS) at GH start (+), Δheight (SDS) 1st year on GH (+), years on GH (+), maternal height (SDS) (+), length (SDS) at birth (+), and the diagnosis of SRS (–) (explained variability 70%; error 0.6 SD). Gain in height (SDS) was explained by: Δheight (SDS) 1st year on GH (+), years on GH (+), height – MPH (SDS) at GH start (–) (explained variability 60%; error 0.7 SD). Conclusions: Algorithms for AH outcomes provides useful information about the potential of long-term growth on GH in short children born SGA.
- Open Access
- 1 March 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (3) , 1229-1237
Observed and Predicted Growth Responses in Prepubertal Children with Growth Disorders: Guidance of Growth Hormone Treatment by Empirical Variables
Context: Information about the expected growth response of children to GH therapy is currently inadequate. Objectives: The aim of the study was to compare observed and expected growth in response to GH in prepubertal children and to propose how these parameters can be used to optimize GH therapy. Indices considered were observed growth, observed growth relative to reference data [height sd score (Ht SDS), change in (Δ) Ht SDS, height velocity (HV)], and observed growth relative to growth predicted from prediction models [Studentized residual (SR)]. Design/Setting/Patients/Intervention: Growth data from KIGS—Pfizer International Growth Database—on prepubertal children aged 1–13 yr with severe GH deficiency (GHD; maxGH Main Outcome Measure: For each patient group, growth responses during the first 2 yr of GH treatment were established. The relationships of HV and ΔHt SDS with SR were determined. Results: Reference data were generated for assessing adequate individual responses. Responses to GH in terms of HV and ΔHt SDS were greatest in children with severe GHD. HV and ΔHt SDS were highly correlated with SR during only the first year of GH treatment (R≈ 0.7; P < 0.001). Conclusions: Decisions on GH therapy regimens should be made using both traditional (HV or ΔHt SDS) and prediction model-derived (SR) indices of growth response.
- 1 March 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (3) , 1229-1237
Open AccessObserved and Predicted Growth Responses in Prepubertal Children with Growth Disorders: Guidance of Growth Hormone Treatment by Empirical Variables
Context: Information about the expected growth response of children to GH therapy is currently inadequate. Objectives: The aim of the study was to compare observed and expected growth in response to GH in prepubertal children and to propose how these parameters can be used to optimize GH therapy. Indices considered were observed growth, observed growth relative to reference data [height sd score (Ht SDS), change in (Δ) Ht SDS, height velocity (HV)], and observed growth relative to growth predicted from prediction models [Studentized residual (SR)]. Design/Setting/Patients/Intervention: Growth data from KIGS—Pfizer International Growth Database—on prepubertal children aged 1–13 yr with severe GH deficiency (GHD; maxGH Main Outcome Measure: For each patient group, growth responses during the first 2 yr of GH treatment were established. The relationships of HV and ΔHt SDS with SR were determined. Results: Reference data were generated for assessing adequate individual responses. Responses to GH in terms of HV and ΔHt SDS were greatest in children with severe GHD. HV and ΔHt SDS were highly correlated with SR during only the first year of GH treatment (R≈ 0.7; P < 0.001). Conclusions: Decisions on GH therapy regimens should be made using both traditional (HV or ΔHt SDS) and prediction model-derived (SR) indices of growth response.
- 1 January 2010
- Vol. 56, 535-42
Validation of functional insulin-like growth factor binding protein-3 measurement by a ligand immunoassay.
Proteolysis of Insulin-like Growth Factor Binding Protein (IGFBP)--3 is a well known mechanism regulating IGF-I bioavailability and IGF-independent actions of IGFBP-3 fragments. Measurement of functional IGFBP-3 can be of use in diagnostics of growth failure or renal impairment. We herein characterize the properties of a commercially available immunoassay for the measurement of functional (IGF-I binding) IGFBP-3. Fragmentation of IGFBP-3 is analyzed by gel filtration, SDS-PAGE, and western ligand and immunoblotting and compared with subsequent measurement of total and functional IGFBP-3 by ELISA/IFA. Furthermore, assay characteristics such as reproducibility, linearity, and sensitivity are surveyed. Functional IGFBP-3 was reproducibly measured (6.8/5.6% Inter-/Intra assay variance). A broad range of linearity (1:50-1:300) and a high sensitivity (0.18 microg/L) allowed reliable measurement of IGF-binding IGFBP-3. Analysis of IGFBP-3 fragments reveals that the assay described only detects intact IGFBP-3. Analysis of 189 serum samples from healthy blood donors showed that on average 84% and 69% of total IGFBP-3 was functional in men and women, respectively (p < 0.01). Functional IGFBP-3 can be measured reliably by the assay system used. Thus, this assay system is suited for the investigation of the diagnostic value of functional IGFBP-3 in human body fluids.
- 1 January 2010
- Vol. 56, 535-42
Validation of functional insulin-like growth factor binding protein-3 measurement by a ligand immunoassay.
Proteolysis of Insulin-like Growth Factor Binding Protein (IGFBP)--3 is a well known mechanism regulating IGF-I bioavailability and IGF-independent actions of IGFBP-3 fragments. Measurement of functional IGFBP-3 can be of use in diagnostics of growth failure or renal impairment. We herein characterize the properties of a commercially available immunoassay for the measurement of functional (IGF-I binding) IGFBP-3. Fragmentation of IGFBP-3 is analyzed by gel filtration, SDS-PAGE, and western ligand and immunoblotting and compared with subsequent measurement of total and functional IGFBP-3 by ELISA/IFA. Furthermore, assay characteristics such as reproducibility, linearity, and sensitivity are surveyed. Functional IGFBP-3 was reproducibly measured (6.8/5.6% Inter-/Intra assay variance). A broad range of linearity (1:50-1:300) and a high sensitivity (0.18 microg/L) allowed reliable measurement of IGF-binding IGFBP-3. Analysis of IGFBP-3 fragments reveals that the assay described only detects intact IGFBP-3. Analysis of 189 serum samples from healthy blood donors showed that on average 84% and 69% of total IGFBP-3 was functional in men and women, respectively (p < 0.01). Functional IGFBP-3 can be measured reliably by the assay system used. Thus, this assay system is suited for the investigation of the diagnostic value of functional IGFBP-3 in human body fluids.
- 1 December 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 72 (Suppl. 2) , 36-40
Noonan Syndrome: Growth to Growth Hormone – The Experience of Observational Studies
Short stature is one of the key features of Noonan syndrome (NS). Attempts have therefore been made to improve height by means of recombinant human growth hormone (rhGH) treatment. Most of these endeavors were carried out either as case studies or observational studies. The overall experience in treating NS is still rather limited, and, in general, it can be said that the NS patients who received GH treatment represent a very narrow segment. The dosages applied in both the case studies and observational studies tended to be higher than those used in the replacement therapy of GH-deficient patients, but lower than in Turner syndrome patients. The NS studies have shown that the overall height gain of patients is small (5–10 cm), and that treatment usually begins at the age of about 10 years, at a height of approximately –3.0 SDS. This small response to treatment reflects the external treatment conditions (i.e. late age at GH start, low GH dose), but may also be associated with the fact that impaired sensitivity to GH is common in NS. Both case studies and observational studies are necessary in order to obtain further evidence about the efficacy and safety of GH treatment in NS.
- 1 December 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 72 (Suppl. 2) , 36-40
Noonan Syndrome: Growth to Growth Hormone – The Experience of Observational Studies
Short stature is one of the key features of Noonan syndrome (NS). Attempts have therefore been made to improve height by means of recombinant human growth hormone (rhGH) treatment. Most of these endeavors were carried out either as case studies or observational studies. The overall experience in treating NS is still rather limited, and, in general, it can be said that the NS patients who received GH treatment represent a very narrow segment. The dosages applied in both the case studies and observational studies tended to be higher than those used in the replacement therapy of GH-deficient patients, but lower than in Turner syndrome patients. The NS studies have shown that the overall height gain of patients is small (5–10 cm), and that treatment usually begins at the age of about 10 years, at a height of approximately –3.0 SDS. This small response to treatment reflects the external treatment conditions (i.e. late age at GH start, low GH dose), but may also be associated with the fact that impaired sensitivity to GH is common in NS. Both case studies and observational studies are necessary in order to obtain further evidence about the efficacy and safety of GH treatment in NS.
- 23 October 2009
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 106 (43) , 703-U19
Treatment of Dwarfism With Recombinant Human Insulin-Like Growth Factor-1
In the past 50 years, a trend has developed in the understanding of growth regulation that is based on the so-called somatomedin hypothesis (e1). This has led to an understanding of the insulin-like growth factor (IGF) system and its different...
- 23 October 2009
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 106 (43) , 703-U19
Treatment of Dwarfism With Recombinant Human Insulin-Like Growth Factor-1
In the past 50 years, a trend has developed in the understanding of growth regulation that is based on the so-called somatomedin hypothesis (e1). This has led to an understanding of the insulin-like growth factor (IGF) system and its different...
- 12 May 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (21) , 1117-1120
Besonderheiten bei der Behandlung mit Wachstumshormon während des Übergangs vom Jugendlichen zum Erwachsenen (Transition)
Bei Erwachsenen mit schwerem Wachstumshormonmangel orientieren sich die Ziele einer Ersatztherapie mit Wachstumshormon (WH) an den Effekten auf die Körperzusammensetzung, die körperliche Leistungsfähigkeit, den Knochenstoffwechsel, den Fettstoffwechsel und die Lebensqualität. Diese Prozesse müssen bei der Behandlung mit WH auch in der Übergangsphase (15. – 25. Lebensjahr) berücksichtigt werden, in der noch nicht alle Entwicklungsprozesse abgeschlossen sind. Eine Unterschreitung des Maximums der WH-Konzentration unter Standard-Stimulationsbedingungen unter 6 µg/l – im Gegensatz zu < 10 µg/l in der Kindheit und < 3 µg/l im Erwachsenenalter – wird in der Transitionsphase als WH-Mangel eingestuft. Die diagnostischen Strategien zur Verifizierung des WH-Mangels in der Übergangsphase, wie sie in internationalen Konsensuskonferenzen vorgeschlagen wurden, werden hier dargelegt. Wie beim Erwachsenen orientiert sich die WH-Dosierung (Startdosis 0,2 – 0,5 mg/Tag) an den individuellen Bedürfnissen und der IGF-I-Konzentration im Blut, welche über 1,0 SDS (Standard Deviation Score) aber unter 2,0 SDS der Norm liegen sollte. Die Betreuung in der Übergangsphase muss durch Endokrinologen erfolgen, die in der Adoleszenz und im Erwachsenenalter Expertise haben, und die Behandlung in strukturierter Form durchführen und dokumentieren. Growth hormone (GH) replacement treatment in adults with severe growth hormone deficiency is based on its known effects on body composition, physical performance, bone and lipid metabolism, and on improvements in the quality of life. These features must be taken into consideration when planning GH treatment of patients who are in the transition phase (aged between 15 and 25 years), because developmental stages may vary. GH deficiency during the transition phase is defined as GH levels under 6 µg/l in a standard stimulation test, compared to < 10 µg/l during childhood and < 3 µg/l during adulthood. We present an overview of the diagnostic strategies recommended at international consensus conferences on the verification ofGH deficiency during the transition phase. In analogy to the GH treatment of adults, the dosaging (dose at start = 0.2 – 0.5 mg/day) should be based on individual requirements as well as IGF-I concentrations in blood (> 1.0 SDS or < 2.0 SDS). GH treatment during the transition phase should be monitored by an endocrinologist with expertise in dealing with adolescent and adult patients, as well as having experience in structuring treatment and documentation.
- 12 May 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (21) , 1117-1120
Besonderheiten bei der Behandlung mit Wachstumshormon während des Übergangs vom Jugendlichen zum Erwachsenen (Transition)
Bei Erwachsenen mit schwerem Wachstumshormonmangel orientieren sich die Ziele einer Ersatztherapie mit Wachstumshormon (WH) an den Effekten auf die Körperzusammensetzung, die körperliche Leistungsfähigkeit, den Knochenstoffwechsel, den Fettstoffwechsel und die Lebensqualität. Diese Prozesse müssen bei der Behandlung mit WH auch in der Übergangsphase (15. – 25. Lebensjahr) berücksichtigt werden, in der noch nicht alle Entwicklungsprozesse abgeschlossen sind. Eine Unterschreitung des Maximums der WH-Konzentration unter Standard-Stimulationsbedingungen unter 6 µg/l – im Gegensatz zu < 10 µg/l in der Kindheit und < 3 µg/l im Erwachsenenalter – wird in der Transitionsphase als WH-Mangel eingestuft. Die diagnostischen Strategien zur Verifizierung des WH-Mangels in der Übergangsphase, wie sie in internationalen Konsensuskonferenzen vorgeschlagen wurden, werden hier dargelegt. Wie beim Erwachsenen orientiert sich die WH-Dosierung (Startdosis 0,2 – 0,5 mg/Tag) an den individuellen Bedürfnissen und der IGF-I-Konzentration im Blut, welche über 1,0 SDS (Standard Deviation Score) aber unter 2,0 SDS der Norm liegen sollte. Die Betreuung in der Übergangsphase muss durch Endokrinologen erfolgen, die in der Adoleszenz und im Erwachsenenalter Expertise haben, und die Behandlung in strukturierter Form durchführen und dokumentieren. Growth hormone (GH) replacement treatment in adults with severe growth hormone deficiency is based on its known effects on body composition, physical performance, bone and lipid metabolism, and on improvements in the quality of life. These features must be taken into consideration when planning GH treatment of patients who are in the transition phase (aged between 15 and 25 years), because developmental stages may vary. GH deficiency during the transition phase is defined as GH levels under 6 µg/l in a standard stimulation test, compared to < 10 µg/l during childhood and < 3 µg/l during adulthood. We present an overview of the diagnostic strategies recommended at international consensus conferences on the verification ofGH deficiency during the transition phase. In analogy to the GH treatment of adults, the dosaging (dose at start = 0.2 – 0.5 mg/day) should be based on individual requirements as well as IGF-I concentrations in blood (> 1.0 SDS or < 2.0 SDS). GH treatment during the transition phase should be monitored by an endocrinologist with expertise in dealing with adolescent and adult patients, as well as having experience in structuring treatment and documentation.